Asad Haider
Stock Analyst at Goldman Sachs
(2.19)
# 2,716
Out of 4,876 analysts
6
Total ratings
100%
Success rate
4.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Initiates: Neutral | $110 | $106.14 | +3.64% | 1 | May 29, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $152.01 | +13.15% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $795.12 | +11.68% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $186.79 | +3.86% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $46.65 | +17.90% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $24.24 | +3.14% | 1 | Apr 8, 2025 |
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $106.14
Upside: +3.64%
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $152.01
Upside: +13.15%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $795.12
Upside: +11.68%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $186.79
Upside: +3.86%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $46.65
Upside: +17.90%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $24.24
Upside: +3.14%